A randomized and double-blind comparison with reboxetine and citalopram in patients with retardant depressive disorder
- VernacularTitle:甲磺酸瑞波西汀与氢溴酸西酞普兰治疗迟缓性抑郁的随机双盲对照研究
- Author:
Weidong CONG
;
Wenyan SHI
;
Yonghua HAN
- Publication Type:Journal Article
- Keywords:
Reboxetine;
Citalopram;
Depression
- From:
Chinese Journal of Primary Medicine and Pharmacy
2008;15(8):1335-1336
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the efficacy and safety of reboxetine and citalopram in treating retardant depression.Methods A total of 59 patients with retardant depression were randomly divided into reboxetine group(n=29)and citalopram group(n=30)for the treatment of 6 weeks.The patients were assessed with the Hamilton depression scale(HAMD)and treatment emergent symptom scale(TESS).Results At the end of 6 weeks,the total scores of HAMD in reboxetine(18.48±6.38)group and citalopram(11.60±4.46)group both significantly decreased(P＜0.001).Between two groups,the efficacy(82.8% and 56.7%)had significant differences(P＜0.05)but side effects had no statistical significance.Conclusion Reboxetine has significant curative efficacy,milder adverse effects and higher safety for treating patients with retardant depression.
